natgillin/translations-raw huggingface dataset:
After the addition of the solvent, the mixture should be well shaken until the powder is completely dissolved in the solvent.
Po dodatku vehikla morate mešanico dobro pretresti, dokler se prašek v vehiklu popolnoma ne raztopi.
In the first 1-2 weeks after a dose of Menitorix it is possible that urine tests to detect Hib infection could give the wrong (false positive) results.
V enem do dveh tednih po cepljenju z odmerkom cepiva Menitorix so rezultati urinskih testov za odkrivanje okužbe s Hib lahko napačni (lažno pozitivni).
The size of the safety database derived from clinical studies and the similarity of this new vaccine to already licensed products were both reasons to accept the database provided, which is supported by the fact that that the available safety data do not indicate any unusual problems.
Velikost varnostne baze podatkov, ki so jo dobili s kliničnimi študijami, in podobnost tega novega cepiva že obstoječim zdravilom z dovoljenji za promet sta bila razloga za sprejetje predložene baze podatkov, kar je podprto z dejstvom, da razpoložljivi podatki o varnosti ne kažejo kakršnih koli nenavadnih težav.
Therefore, the CHMP considered that the size of the safety database was already satisfactory before provision of the additional clinical study data and that the new information submitted brings the total to well above the minimum suggested in the CHMP guideline.
Zato je CHMP menil, da je bila velikost baze podatkov zadovoljiva že pred preskrbo dodatnih kliničnih študijskih podatkov in da so nove predložene informacije zagotovile, da je celotna količina podatkov znatno večja od tiste, predlagane v smernici odbora CHMP.
The VWP considered the new submitted data along with the already submitted data and agreed that the safety and immunogenicity data are adequate and satisfactory to support the approval of Menitorix.
Skupina VWP je upoštevala nove predložene podatke skupaj z že predloženimi podatki in se strinjala, da so podatki o varnosti in imunogenosti primerni in zadovoljivi za podporo odobritve dovoljenja za promet z zdravilom Menitorix.
• if your child has a bleeding problem or bruises easily.
• če ima otrok težave s krvavitvami ali hitrim pojavom modric.
Strength *
Jakost*
The post-marketing data raised no new concerns and the satisfactory safety profile of the vaccine was supported by the safety data reported in PSUR 3 from use of Menitorix in approximately 0.6 million toddlers as a booster dose for Hib and MenC in the UK.
Podatki po trženju niso sprožili novih zadržkov, zadovoljiv varnostni profil cepiva pa so podprli tudi podatki o varnosti, o katerih so poročali v poročilu PSUR 3 in ki so izvirali iz uporabe zdravila Menitorix kot poživitvenega odmerka proti Hib in MenC pri približno 0,6 milijona majhnih otrok v Združenem kraljestvu.
Do not use Menitorix after the expiry date which is stated on the carton.
Cepiva Menitorix ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
In the event of either being observed, discard the vaccine.
Če opazite karkoli od tega, cepivo zavrzite.
All subjects responded immunologically to a challenge dose of 10 µg of unconjugated group C meningococcal polysaccharide with a thirty-three-fold increase in SBA titres demonstrating the immune memory induced by the primary vaccination course.
Vse osebe so se imunološko odzvale na cepljenje z 10 µg nekonjugiranega polisaharida meningokokov skupine C s 33-kratnim povečanjem titrov SBA, kar kaže na prisotnost imunskega spomina po osnovnem cepljenju.
The following have not been reported in association with administration of Menitorix but have occurred very rarely during routine use of licensed meningococcal group C conjugate vaccines:
O naslednjih neželenih učinkih niso poročali v povezavi z uporabo cepiva Menitorix, vendar pa so o njih zelo redko poročali pri rutinski uporabi uradno potrjenih konjugiranih cepiv proti meningokokom skupine C:
If your child receives more Menitorix than he/she should It is very unlikely that your child will receive too much or too little vaccine because each dose is provided in a separate vial and the vaccine is given by a doctor or nurse.
Če je otrok prejel večji odmerek cepiva Menitorix, kot bi smel Možnost, da bi otrok prejel prevelik ali premajhen odmerek cepiva je majhna, saj je vsak odmerek na voljo v posebni viali, cepivo pa bo otroku vedno dal zdravnik ali medicinska sestra.
• Pain, redness or swelling at the site of the injection
• Bolečina, rdečina ali oteklina na mestu injiciranja.
It is very important that your child has immediate medical treatment for any severe allergic reaction.
Zelo pomembno je, da je v primeru pojava hude alergijske reakcije, nemudoma na voljo zdravniška pomoč.
Belgium GlaxoSmithkline Biologicals S.A., 89 rue de l'Institut, B-1330 Rixensart, Belgium
Belgija GlaxoSmithkline Biologicals S.A., 89 rue de l'Institut, B1330 Rixensart, Belgija
Other side effects which have occurred very rarely (in less than 1 per 10,000 doses of vaccine) in the days or weeks after vaccination with Menitorix include:
Drugi zelo redki neželeni učinki (pri manj kot 1 od 10.000 odmerkov cepiva), ki so se pojavili v nekaj dneh ali tednih po cepljenju s cepivom Menitorix, so:
Menitorix must not be mixed with any other vaccine in the same syringe.
Cepiva Menitorix se ne sme mešati z drugimi cepivi v isti in brizgi.
The CHMP considers that under the conditions of study, Menitorix elicits sufficient immune responses to both conjugate components to provide protection that is expected to be at least as good as that of licensed comparators.
CHMP meni, da je pod študijskimi pogoji zdravilo Menitorix sprožilo zadostne imunske odzive na oba sestavna dela konjugata in tako nudi zadostno zaščito, za katero se pričakuje, da bo vsaj tako dobra kot pri primerjalnih zdravilih z dovoljenjem za promet.
• Post-marketing experience
• Izkušnje po pridobitvi dovoljenja za promet
Menitorix can be given from the age of 2 months after birth onwards but it is not known if protection against Hib and MenC will be as good as in children born at term.
Otrok lahko cepivo Menitorix prejme v starosti od 2 mesecev po rojstvu, vendar pa ni znano, če je zaščita proti Hib in MenC enako dobra kot pri otrocih, ki so rojeni ob normalnem času.
• Fever of 39.5°C or above
• Telesna temperatura 39,5 °C ali višja.
The CHMP adopted a List of Outstanding Issues for the Applicant/MAH to address and requested the Vaccine Working Party (VWP) to consider the same outstanding issues.
CHMP je sprejel seznam izrazitih zadržkov, ki jih mora predlagatelj/imetnik dovoljenja za promet z zdravilom primerno rešiti, in zahteval od delovne skupine za cepivo (VWP), da omenjene izrazite zadržke upošteva.
In order to further justify the adequacy of the safety database in children primed and/or boosted with Menitorix, the Applicant/MAH provided additional data from two recently reported studies, augmenting the total database with an additional 1131 subjects who received a total of 2992 doses of Menitorix.
Da bi še bolj upravičili primernost baze podatkov o varnosti pri otrocih, ki so prejeli osnovno cepljenje in/ali poživitveni odmerek cepiva Menitorix, je predlagatelj/imetnik dovoljenja za promet z zdravilom priskrbel dodatne podatke o dveh nedavnih študijah, ki sta celotno bazo podatkov povečali za dodatnih 1.131 oseb, ki so prejele vsega skupaj 2.992 odmerkov zdravila Menitorix.
If you forget to take your child for vaccination with Menitorix Your doctor or nurse will advise when your child should attend for these injections.
Če ste pozabili na otrokovo cepljenje s cepivom Menitorix Zdravnik ali medicinska sestra vas bosta obvestila kdaj mora biti otrok cepljen.
• Generally feeling unwell
• Splošno slabo počutje.
*GlaxoSmithKline combination vaccine
*Kombinirano cepivo podjetja GlaxoSmithKline
Individuals with complement deficiencies and individuals with functional or anatomical asplenia may mount an immune response to Hib and MenC conjugate vaccines; however the degree of protection that would be afforded is unknown.
Osebe s pomanjkanjem komplementa in osebe s funkcionalno ali anatomsko asplenijo lahko dosežejo imunski odziv na konjugirana cepiva proti Hib in MenC, vendar pa stopnja dosežene zaščite ni znana.
The similarity of Menitorix to already licensed products and the fact that the available safety data do not indicate any unusual problems are both reasons to accept the database provided.
Podobnost zdravila Menitorix z že obstoječimi zdravili z dovoljenjem za promet in dejstvo, da razpoložljivi varnostni podatki ne nakazujejo nenavadnih težav sta razloga za sprejem te nove predstavljene baze podatkov.
There were no significant differences between the two groups in the proportions with SBA-MenC titers of at least 1:8 or anti-PRP antibody concentrations of at least 0.15 µg/ml.
Med obema skupinama ni bilo pomembne razlike v deležih oseb s titri SBA-MenC vsaj 1:8 ali koncentracijo protiteles anti-PRP vsaj 0,15 µg/ml.
The Company has already planned to assess long-term antibody persistence and, to complete this procedure, should formally commit to providing to the relevant national competent authorities for assessment the data from longer-term follow-up of studies 010/022 and 013 with anticipated timelines.
Podjetje je že načrtovalo ocenjevanje dolgotrajne prisotnosti protiteles in se mora za končanje tega postopka formalno posvetiti zagotavljanju podatkov iz spremljanja na dolgi rok za študiji 010/022 in 013 v pričakovanih rokih primernim nacionalnim pristojnim organom.
Following the initial assessment, the CHMP considered that under the conditions of study, the safety and immunogenicity data provided were adequate to assess the risk-benefit relationship for the use of Menitorix for priming and/or boosting and could be used to assess the likely protection that will be afforded by the vaccine.
Po začetnem vrednotenju je CHMP menil, da so bili glede na pogoje študije predloženi zadostni podatki o varnosti in imunogenosti za ocenjevanje razmerja med koristmi in tveganji uporabe zdravila Menitorix za osnovno in/ali poživitveno cepljenje in se lahko uporabijo za ovrednotenje zaščite, ki jo bo po vsej verjetnosti nudilo cepivo.
Based on the SBA-MenC titres and SBA GMT obtained in studies and because of the effectiveness of single doses of mono-component MenC conjugate vaccines in unprimed toddlers, the Applicant/MAH concluded that the long-term efficacy of Menitorix will be at least as good, if not better, as that observed in this age group in the UK and Canada.
Na podlagi titrov SBA-MenC in ravni SBA GMT, ki so jih dobili v študijah, ter zaradi učinkovitosti enkratnega odmerka enokomponentnih konjugiranih cepiv proti virusu MenC pri majhnih otrocih, ki niso prejeli prvotnega odmerka, je predlagatelj/imetnik dovoljenja za promet z zdravilom zaključil, da bo dolgotrajna učinkovitost zdravila Menitorix vsaj tako dobra kot tista, ki so jo opazili v tej starostni skupini v Združenemu kraljestvu in Kanadi.
In individuals with impaired immune responsiveness (whether due to the use of immunosuppressive therapy, a genetic defect, human immunodeficiency virus (HIV) infection, or other causes) a protective immune response to Hib and MenC conjugate vaccines may not be obtained.
Pri osebah z okvarjenim imunskim odzivom (zaradi zdravljenja z imunosupresivnimi zdravili, genetske okvare, okužbe z virusom humane imunske pomanjkljivosti (HIV) ali drugih vzrokov) zaščitni imunski odziv na konjugirana cepiva proti Hib in MenC morda ne bo dosežen.
Menitorix should not be given:
Otrok cepiva Menitorix ne sme prejeti:
The Applicant/MAH is requested to commit to submitting for assessment, to the relevant national competent authorities, the results from the long-term antibody persistence data from the ongoing studies with Menitorix i.e. subjects from booster studies 013 and 022 are being followed up for antibody persistence as follows: o Over 4 years of follow up of subjects from study 013 in studies 027, 028 and 029. o Five years follow-up from 010/022 in subsequent studies 023, 024, 025 and 026.
Predlagatelj/imetnik dovoljenja za promet z zdravilom se mora obvezati, da bo pristojnim nacionalnim organom predložil rezultate podatkov o dolgotrajni prisotnosti protiteles iz trenutno potekajočih študij z zdravilom Menitorix, tj. pri osebah iz študij poživitvenega cepljenja 013 in 022 se spremlja prisotnost protiteles, kot sledi: o več kot štiri leta spremljanja oseb iz študije 013 v študijah 027, 028 in 029; o pet let spremljanja iz študij 010/022 v naknadnih študijah 023, 024, 025 in 026.
Allergic reactions (these can be recognised by itchy rash of the hands and feet, swelling of the eyes and face, difficulty in breathing or swallowing), swelling of the glands, dizziness, convulsions (fits) with high temperature, unusual muscle slackness, headache.
Alergijske reakcije (ki se lahko kažejo s srbečim izpuščajem po rokah ali nogah, oteklino oči in obraza, težkim dihanjem ali požiranjem), oteklina bezgavk, omotica, krči z visoko telesno temperaturo, neobičajna mlahavost mišic in glavobol.
Take special care with Menitorix:
Bodite posebno pozorni pri uporabi cepiva Menitorix:
GMC (micrograms/ml)
GMC (mikrogrami/ml)
The most recent updates to the SPC serve to reflect the total data available thus far.
Najnovejše posodobitve Povzetka glavnih značilnosti zdravila so odsev vseh doslej razpoložljivih podatkov.
Since Hib capsular polysaccharide antigen is excreted in the urine, a positive urine antigen test can be observed within 1-2 weeks following vaccination.
Ker se kapsularni polisaharidni antigen Hib izloča z urinom je možno, da so 1-2 tedna po cepljenju urinski testi za dokazovanje antigena lažno pozitivni.
In order to discuss the implication for long-term protection against MenC of the 18-month post booster data in study 022, in particular for those receiving primary vaccination with Menitorix, the Applicant/MAH reviewed the available data relating to antibody titres and vaccine effectiveness after the administration of a single dose of mono-component vaccines in the second year of life.
Za razpravo o posledicah podatkov, dobljenih 18 mesecev po poživitvenem cepljenju, v študiji 022 za dolgoročno zaščito proti virusu MenC, še posebej za tiste bolnike, ki so prejeli osnovno cepljenje z zdravilom Menitorix, je predlagatelj/imetnik dovoljenja za promet z zdravilom pregledal razpoložljive podatke, ki se nanašajo na titre protiteles in učinkovitost cepiva po dajanju enega samega odmerka enokomponentnih cepiv v drugem letu starosti.
Solvent: sodium chloride, water for injections.
Vehikel: natrijev klorid in voda za injekcije.
Menitorix is available in packs of 1 or 10 with 2 separate needles or without needles.
Cepivo Menitorix je na voljo v pakiranjih po 1 ali 10, skupaj z 2 priloženima injekcijskima iglama ali brez.
If you are concerned about the dose or doses that have been given, please talk to your doctor or nurse.
Če ste glede odmerka ali odmerkov cepiva, ki jih je otrok prejel zaskrbljeni, se posvetujte z zdravnikom ali z medicinsko sestro.
No data are available on subcutaneous administration of Menitorix, therefore the possibility of any toxicity or reduced efficacy that might occur with this route of administration is unknown.
Podatki o subkutanem dajanju cepiva Menitorix niso na voljo, zato možnost pojava toksičnih učinkov ali manjše učinkovitosti cepiva po subkutanem dajanju ni znana.
Powder and solvent for solution for injection 1 vial: Powder
Prašek in vehikel za raztopino za injiciranje 1 viala: prašek
♦ Uncommon (in less than 1 per 100 but more than 1 per 1,000 doses of vaccine)
♦ Občasni (pri manj kot 1 od 100, vendar več kot 1 od 1.000 odmerkov cepiva)
Although Menitorix contains tetanus toxoid (inactivated bacterial toxin), which is used to immunise people against tetanus (lockjaw), it is still necessary that your child should receive the recommended childhood vaccinations against tetanus.
Cepivo Menitorix vsebuje tetanusni toksoid (inaktivirani bakterijski toksin), ki ga uporabljamo za cepljenje ljudi proti tetanusu (mrtvičnemu krču), vendar pa mora otrok kljub temu biti v otroštvu cepljen tudi s priporočenim cepivom proti tetanusu.
The safety and immunogenicity data provided are adequate to establish that the risk-benefit relationship for the use of Menitorix for priming in infancy and/or boosting in the second year of life is favourable.
Predloženi podatki o varnosti in imunogenosti zadostujejo za ugotovitev, da je razmerje med tveganji in koristmi za zdravilo Menitorix pri osnovnem cepljenju dojenčkov in/ali poživitvenem cepljenju v drugem letu življenja ugodno.
Skin and subcutaneous tissue disorders: uncommon: dermatitis atopic rare: rash
Bolezni kože in podkožja: Občasni: atopični dermatitis Redki: izpuščaj
Compared to the two control groups that received either Menitorix or MMR alone the immune responses to the antigens in both vaccines were not affected by concomitant administration.
V primerjavi z dvema kontrolnima skupinama, v katerih so osebe prejele cepivo Menitorix ali cepivo proti MMR samo, sočasno cepljenje ni vplivalo na imunski odziv na antigene v obeh cepivih.
It is usual to wait until the child is better before giving the vaccine.
Cepljenje je običajno treba odložiti, dokler otrok ne ozdravi.
• Fever (temperature of 38oC or above)
• Zvišana telesna temperatura (38 oC ali višja).
They include: Collapse or shock, the child not responding to his or her parents for a time after vaccination, fainting, convulsions in children who have had them before, lack of sensation or an increased sensation (for example pain, pins and needles or itching at the injection site), joint pain, or purple spots or patches under the skin.
Ti so vključevali: kolaps ali šok, neodziv otroka na starše nekaj časa po cepljenju, omedlevico, krče pri otrocih, ki so jih imeli že prej, zmanjšano ali preveliko občutljivost (na primer bolečina, zbadanje ali srbenje na mestu injiciranja), bolečine v sklepih ali škrlatne pege ali zaplate pod kožo.
The Applicant/MAH considers that the extent of the total safety database is entirely consistent with the recommendations of the CHMP Guideline on Clinical Evaluation of New Vaccines and is sufficiently large to identify uncommon events.
Predlagatelj/imetnik dovoljenja za promet z zdravilom meni, da je velikost celotne baze podatkov o varnosti popolnoma skladna s priporočili odbora CHMP, opredeljenimi v smernicah za klinično ocenjevanje novih cepiv in da je baza dovolj velika za prepoznanje občasnih neželenih učinkov.
The total safety database derived from clinical studies now consists of 3293 infants vaccinated with Menitorix either as a primary course or as a booster and 578 infants vaccinated with 1713 doses of closely related Hib-MenC formulations and therefore exceeds that suggested by the CHMP Guideline for truly new vaccines.
Celotna baza podatkov o varnosti, ki je bila dobljena iz kliničnih študij, trenutno vključuje 3.293 dojenčkov, ki so jih cepili z zdravilom Menitorix bodisi kot osnovno cepivo ali kot poživitveno cepivo, in 578 dojenčkov, ki so jih cepili s 1.713 odmerki sorodnih formulacij Hib-MenC, in zato presega količino, ki jo predlaga smernica odbora CHMP za povsem nova cepiva.
The immunogenicity data indicates that Menitorix will be at least as effective as the licensed PRP-T and MenC conjugate vaccines when used for priming and/or for boosting in accordance with the SPC.
Podatki o imunogenosti kažejo, da bo zdravilo Menitorix vsaj tako učinkovito kot odobrena konjugirana cepiva proti PRP-T in MenC, če se uporablja za osnovno cepljenje in/ali poživitveno cepljenje v skladu s Povzetkom glavnih značilnosti zdravila.
The data from SPCs, literature and generated during clinical development combined with recent surveillance data from the United Kingdom and Canada suggest that vaccine effectiveness remained high in unprimed subjects who had been vaccinated in their second year of life with a single dose.
Podatki iz povzetka glavnih značilnosti zdravila in literature ter podatki, do katerih so prišli med kliničnim razvojem v kombinaciji z zadnjimi podatki spremljanja iz Združenega kraljestva in Kanade, kažejo, da je učinkovitost cepiva ostala visoka pri osebah, ki niso prejele osnovnega cepljenja in ki so se cepile v drugem letu življenja z enim samim odmerkom.
Other diagnostic tests, not based on the detection of the capsular antigen in urine, should be used to confirm Hib disease during this period.
V tem času je treba za potrditev bolezni, povzročene s Hib, uporabiti druge diagnostične teste, ki ne temeljijo na dokazu kapsularnega antigena v urinu.
However, the CHMP considered that there were concerns regarding the long-term antibody persistence, the adequacy of the safety data set in the light of the CHMP Guideline on Clinical Evaluation of New Vaccines, and the indication of Menitorix for both priming and boosting.
Vendar pa je CHMP menil, da obstajajo zadržki glede prisotnosti protiteles na dolgi rok, primernosti varnostnih podatkov glede na smernice CHMP za klinično ocenjevanje novih cepiv in indikacije zdravila Menitorix tako za osnovne kot poživitvene odmerke.
It is recommended that infants who receive Menitorix for the first dose should also receive this vaccine for the second and third doses of the primary vaccination course.
Priporočljivo je, da otrok, ki je bil osnovno cepljen s prvim odmerkom cepiva Menitorix, med osnovnim cepljenjem prejme tudi drugi in tretji odmerek istega cepiva.
It cannot protect against meningitis caused by other bacteria or viruses, including other types and groups of Haemophilus or Neisseria bacteria.
Cepivo ne more ščititi pred meningitisom, ki ga povzročijo druge bakterije ali virusi, vključno z drugimi tipi bakterije Haemophilus influenzae in skupinami bakterij Neisseria meningitidis.
This vaccine cannot cause MenC or Hib infections.
To cepivo ne more povzročiti okužbe z MenC ali Hib.
After three doses N=330†
Po treh odmerkih N = 330†
Menitorix-containing regimens were not more reactogenic than the comparative regimens in which the same total range of antigens was administered.
Načini zdravljenja, ki vključujejo zdravilo Menitorix, niso povzročali večje reaktivnosti kot primerljivi načini zdravljenja, pri katerih je bila tudi dana celotna paleta antigenov.
After two doses N=93
Po dveh odmerkih N = 93
Severe skin reactions, collapse or shock-like state (hypotonic-hyporesponsiveness episode), faints, seizures in patients with pre-existing seizure disorders, hypoaesthesia, paraesthesia, relapse of nephrotic syndrome, arthralgia, petechiae and/or purpura.
Hude kožne reakcije, kolaps ali šoku podobno stanje (hipotonična-hiporesponzivna epizoda), omedlevica, epileptični napadi, pri bolnikih z epilepsijo, hipestezija, parestezija, ponovitev nefrotskega sindroma, artralgija, petehije in/ali purpura.
What Menitorix is and what it is used for Before your child receives Menitorix How Menitorix is given Possible side effects
Kaj je cepivo Menitorix in za kaj ga uporabljamo Kaj morate vedeti, preden bo otrok cepljen s cepivom Menitorix Kako se cepivo Menitorix uporablja Možni neželeni učinki
* Hib PRP - Haemophilus influenzae type B polyribosylribitol phosphate TT - tetanus toxoid
* Hib PRP - Haemophilus influenzae tipa B poliribozilribitol fosfat TT - tetanusni toksoid
• if your child has previously had any allergic reaction to Menitorix, to any Hib or MenC vaccine, to tetanus toxoid or to any other ingredient present in the vaccine (see section 6).
• če se je po predhodnem cepljenju s cepivom Menitorix, katerimkoli drugim cepivom proti Hib ali proti MenC ali tetanusnim toksoidom pri otroku pojavila alergijska reakcija ali če je otrok preobčutljiv za katerokoli sestavino cepiva (glejte poglavje 6).
However, following several reports of suspected ADRs, section 4.8 of the Menitorix SPC was updated.
Vendar pa je predlagatelj po nekaj poročilih o sumu na neželene reakcije posodobil poglavje 4.8 Povzetka glavnih značilnosti zdravila za zdravilo Menitorix.
Clinical alertness to the possibility of co-incidental meningitis should be maintained.
Upoštevati je treba možnost sočasnega pojava meningitisa.